Researchers identify therapies to limit COVID-19 risk in people with Down syndrome
Australian Institute for Bioengineering and Nanotechnology (AIBN) Senior Research Fellow Dr Mohammed Shaker and Phenomics Australia Scientific Director Professor Ernst Wolvetang, head of the In vitro Genome Engineering and